Cadrenal Therapeutics, Inc. (CVKD)
Nasdaq: CVKD · Pharmaceutical Preparations · Ponte Vedra, FL · filing with the SEC since 2022
Who runs Cadrenal Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Pham Quang X
Chairman and CEO. First filing Jan 2023, latest Oct 13, 2026, 18 filings in all.
Officers reporting now
3
of 6 people with a filing in the last fifteen months
Directors reporting now
3
10 people on the record since 2023
Officerssales are open-market, Oct 13, 2025 to Oct 13, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Pham Quang X | Chairman and CEO | Jan 2023 | Oct 13, 2026 | 25 · $400,000 |
| Cole Jeffrey Scott | Chief Operating Officer | Apr 2024 | Oct 13, 2026 | none |
| Szot Matthew K | Chief Financial Officer | Jan 2023 | Dec 31, 2025 | 4 · $100,000 |
Directorssales are open-market, Oct 13, 2025 to Oct 13, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Golden Lee Scott | director | Dec 2025 | Oct 13, 2026 | none |
| Murphy John Raymond | director | Jan 2023 | Oct 13, 2026 | none |
| Wilson Glynn | director | Jan 2023 | Oct 13, 2026 | none |
Earlier names on the record4, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.